RLMD - Relmada Therapeutics EPS misses by $0.25 March, 23 2021 04:31 PM Relmada Therapeutics Inc. Relmada Therapeutics (RLMD): FY GAAP EPS of -$3.81 misses by $0.25.Cash, cash equivalents, and short-term investment of $117.1M.Press Release For further details see: Relmada Therapeutics EPS misses by $0.25